Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

Sydney University signs agrifood innovation agreement with FAO

interpack 2029 will have a new runtime

Jet Technologies partners with coffee processing specialist Neuhaus Neotec

Arla Foods acquires Aussie cottage cheese producer

Ferrero appoints new GM to lead Australia and NZ

National standards for pain management education now available

Daniel Wyner appointed Lumary CEO

Home care safeguards when disasters hit

"Historic legislation" allows authorised nurses to prescribe PBS medicines

You see what others miss

AMCRC announces project to evaluate local titanium powder

NSW to invest $12bn to rebuild Hunter train manufacturing

Orica hydrogen hub project reaches major investment milestone

Dual-bubble method removes more microplastics from wastewater

Energy crisis will have long‍-‍term effects: Australian Industry Group